Strategy

US Growth Equities

The Driehaus US Growth Equities team focuses on investing in US-listed equities of public companies with market capitalizations between $100 million and $15 billion, through the Driehaus Micro Cap Growth, Driehaus Small Cap Growth, Driehaus Small/Mid Cap Growth and Driehaus Life Sciences strategies. The strategies provide investors with high active share portfolios of companies experiencing positive fundamental change in addition to exposure to positive growth inflections, earnings surprises and earnings revisions, factors that are positively correlated to alpha generation. The team is led by Jeff James who began his portfolio management career at Driehaus in 1998. He is supported by six analysts that combined have over 50 years of Driehaus research experience.

Institutional Investors

Our institutional sales team will be pleased to address questions and requests related to separately managed accounts and/or institutional commingled vehicles that employ our investment strategies.

Ask Us!

Driehaus Micro Cap Growth Strategy

View Details
Back

Driehaus Micro Cap Growth Strategy

The strategy seeks to outperform the Russell Microcap® Growth Index over full market cycles.

Facts

Strategy Inception Date
Jan 01, 1996
Total Strategy Assets
As of Mar 31, 2019
$1,031M

Separately Managed Accounts

Open to New Investors
No

Funds

Driehaus Small Cap Growth Strategy

View Details
Back

Driehaus Small Cap Growth Strategy

The strategy seeks to outperform the Russell 2000® Growth Index over full market cycles.

Facts

Strategy Inception Date
Jan 01, 1980
Total Strategy Assets
As of Mar 31, 2019
$388M

Separately Managed Accounts

Open to New Investors
Yes

Funds

Driehaus Small/Mid Cap Growth Strategy

View Details
Back

Driehaus Small/Mid Cap Growth Strategy

The strategy seeks to outperform the Russell 2500® Growth Index over full market cycles.

Facts

Strategy Inception Date
Feb 01, 2012
Total Strategy Assets
As of Mar 31, 2019
$38M

Separately Managed Accounts

Open to New Investors
Yes

Driehaus Life Sciences Strategy

View Details
Back

Driehaus Life Sciences Strategy

The strategy intends to exploit the inefficiencies in how markets assign risk to development-stage and early-commercial stage healthcare companies.

Facts

Strategy Inception Date
Feb 01, 2019
Total Strategy Assets
As of Mar 31, 2019
$14M

Separately Managed Accounts

Open to New Investors
Yes